Dr. Jeffrey M. Dayno is the President and CEO of Harmony Biosciences Holdings, Inc., having taken the role permanently in April 2023 after serving as Interim CEO since January 2023. With a strong medical background, Dr. Dayno holds an M.D....

Dr. Jeffrey M. Dayno is the President and CEO of Harmony Biosciences Holdings, Inc., having taken the role permanently in April 2023 after serving as Interim CEO since January 2023. With a strong medical background, Dr. Dayno holds an M.D. from Temple University School of Medicine and has more than 20 years of experience in the pharmaceutical industry. His career includes key roles at notable companies such as Merck & Co., Inc., where he contributed to global medical affairs, and ViroPharma, Inc., prior to its acquisition by Shire Pharmaceuticals. Before his leadership at Harmony, he was the Chief Medical Officer at Zyla Life Sciences. Beyond his corporate roles, Dr. Dayno is also known for his involvement with the Philadelphia Stroke Council, where he served as Chairman, highlighting his commitment to healthcare advancements. In his current role, he aims to enhance Harmony's pipeline while driving clinical development programs and strengthening the company's financial health. His strategic focus has already shown results, with significant revenue achievements; for instance, in 2023, the company reported net product revenues of $582 million. Dr. Dayno’s approach to leadership is practical and results-oriented, aligning medical goals with business objectives, thus positioning Harmony for future growth.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Harmony Biosciences Holdings, Inc. CEOs

H

Dr. Jeffrey M. Dayno

CEO of Harmony Biosciences Holdings, Inc.

Education

M.D. from Temple University School of Medicine

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1958 - 67 years ago

CEO of Harmony Biosciences Holdings, Inc. for

2 years 4 months (Jan 2023 - Present)

Previous Experience

Chief Medical Officer of Harmony Biosciences Holdings, Inc.

Rivals

Competitors/colleagues of Dr. Jeffrey M. Dayno

Holdings

See how much did Dr. Jeffrey M. Dayno make over time.

As President and CEO of Harmony Biosciences, Dr. Jeffrey M. Dayno holds 125,000 options in the company, reflecting a strong ownership stake. The options he received, valued at about $3.5 million based on current figures, profile his commitment to the...

As President and CEO of Harmony Biosciences, Dr. Jeffrey M. Dayno holds 125,000 options in the company, reflecting a strong ownership stake. The options he received, valued at about $3.5 million based on current figures, profile his commitment to the company’s success. His significant equity means that a large part of his potential wealth is tied to Harmony’s performance, encouraging alignment with shareholder interests. Early in his appointment, he also secured a retention bonus of $200,000. Over time, Dr. Dayno has navigated fluctuations in his wealth, primarily tied to company growth and product revenues. Harmony's performance under his leadership showcased robust revenue which indicates a strong potential for growth in future valuations. His financial interests are tightly aligned with the direction and health of the company he leads.

Total Stock Sold

$3.65M

HRMY

$3.65M

80,000 HRMY shares

What if they kept their stock?

If Dr. Jeffrey M. Dayno didn't sell their stock, today they would have:
Extra HRMY80,000 shares worth $2.96M.
This is -18.92% and $690.94K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Jeffrey M. Dayno.

HRMY

$900.33K

HRMY at $60.02/share

Nov 3, 2022

Sale

HRMY

$826.56K

HRMY at $55.10/share

Nov 1, 2022

Sale

HRMY

$790.77K

HRMY at $43.45/share

Oct 19, 2021

Sale

HRMY

$72.18K

HRMY at $40.10/share

Oct 6, 2021

Sale

HRMY

$375.78K

HRMY at $37.58/share

Sep 7, 2021

Sale

HRMY

$350.84K

HRMY at $35.08/share

Aug 26, 2021

Sale

HRMY

$300.63K

HRMY at $30.21/share

Aug 10, 2021

Sale

HRMY

$1.50K

HRMY at $30.00/share

Jul 22, 2021

Sale

Compensation History

See how much did Dr. Jeffrey M. Dayno make over time.

In 2023, Dr. Jeffrey M. Dayno's total compensation reached $4.45 million, which includes a base salary of $650,000 and a one-time cash retention bonus of $200,000. Additionally, he has been awarded stock options valued at around $3.18 million upon grant, demonstrating the board's confidence in his leadership. With a bonus potential tied to performance metrics focusing on net product revenue and clinical development goals, Dr. Dayno's compensation structure is designed to incentivize high performance. His previous salary as Chief Medical Officer was $530,000, highlighting a substantial increase reflecting his new role as CEO. This compensation strategy is aligned with the company's goal of rewarding leadership that can drive growth while meeting performance benchmarks.

Year

2023

Total Compensation

$4.41M

Salary

$650.00K

Board Justification

The compensation program is designed to attract, motivate, and reward executives while aligning their interests with those of stockholders.

Bonus

$200.00K

Board Justification

One-time cash retention bonus paid in January 2023, subject to repayment if employment is terminated for cause or voluntarily before December 15, 2024.

Other

$13.92K

Board Justification

401(k) matching contributions, life insurance premiums, long-term disability premiums.

Restricted Stock

$3.55M(125K Stock Options)

Board Justification

Stock option granted in connection with his appointment as President and CEO, vesting 50% on May 25, 2025 and the remaining 50% in 24 equal monthly installments thereafter, subject to continued service.

Performance Metrics

Performance metrics include Net Product Revenue, clinical development programs, corporate transactions, financial health, and talent and culture.

Other Harmony Biosciences Holdings, Inc. CEOs

Here are other CEOs of Harmony Biosciences Holdings, Inc.

John C. Jacobs

Founder and Ex-CEO of Harmony Biosciences Holdings, Inc.

November 2020 - January 2023